アジア太平洋地域の生物製剤CMO (医薬品製造受託機関) 施設

当レポートでは、アジア太平洋地域 (中国、台湾、韓国、日本、インド、シンガポールなど) における50以上のCMO (医薬品製造受託機関) について調査分析し、製造能力、設備設計、製品ライン、規制認証、チーム分布、財務実績、技術、施設の拡張計画などについて、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 企業別のデータと分析

• 企業概要
• 製造サイト
• 施設設計
• プラント容量
• バッチサイズ
• GMP認証
• 製品
• 製造サービス
• プロジェクト
• パートナーシップとコラボレーション
• 容量計画と将来の拡張
• インタビュー
• 業界ニュースとアップデート
• SWOT分析
• 参考文献

• 大中華圏
• 1. AMARAN BIOTECHNOLOGY
• 2. BOEHRINGER INGELHEIM
• 3. CMAB BIOPHARMA
• 4. CELLULAR BIOMEDICINE GROUP
• 5. CHIME BIOLOGICS
• 6. CP GOUJIAN PHARMA
• 7. EIRGENIX
• 8. INNOVENT BIOLOGICS
• 9. LONZA CHINA
• 10. MABPLEX
• 11. MYCENAX BIOTECH
• 12. OBIO TECHNOLOGY
• 13. ORIENT PHARMA
• 14. SINOBIOWAY
• 15. TARON SOLUTIONS
• 16. UNICOCELL
• 17. UNITED BIOPHARMA
• 18. WUXI APPTEC
• 19. 3S BIO

• 韓国
• 20. ANTEROGEN
• 21. BINEX
• 22. EUBIOLOGICS
• 23. HANMI PHARMA
• 24. KOLON LIFE SCIENCES
• 25. MASTHERCELL
• 26. SAMSUNG BIOLOGICS

• 日本
• 27. AGC BIOLOGICS
• 28. AJINOMOTO BIO- PHARMA
• 29. BUSHU PHARMACEUTICALS
• 30. HITACHI CHEMICAL
• 31. ID PHARMA
• 32. MEDINET
• 33. PHARMABIO
• 34. TAKARA BIO
• 35. TOYOBO

• インド
• 36. CLONZ BIOTECH
• 37. INTAS PHARMACEUTICALS
• 38. KEMWELL BIOPHARMA
• 39. STELIS BIOSOURCE
• 40. SYNGENE
• 41. ENZENE BIOLOGICS

• オーストラリア
• 42. CELL THERAPIES
• 43. PFIZER CENTREONE
• 44. LUINA BIO SEA

• 東南アジア
• 45. BIOCON
• 46. ESCO ASTER
• 47. INNO BIOLOGICS
• 48. LONZA AG SINGAPORE
• 49. PT. KALBIO GLOBAL MEDIKA(KGM)
• 50. TCELS

第3章 地域別のデータとCMOの分析

• 製品
• 技術と製造サービス
• 製造ライン
• GMP認証
• 施設規模・設計・容量計画
• チーム規模・分布
• PESTEL分析

第4章 その他のレポート

• 参考文献
• 免責事項
• 出版社について
• その他のレポート

LIST OF TABLES

SUMMARY OF CONTRACT MANUFACTURERS

• Table 1: List of Top 50 Contract Manufacturers across Asia covered in the Report
• Table 2: Management Team
• Table 3: Projects Completed Thus far
• Table 4: Batch Size and Capacity

REGION WISE ANALYSIS

CHINA, TAIWAN, INDIA KOREA, JAPAN, AUSTRALIA, SEA

• Table 5: Technologies and Manufacturing Services Offered by CMOs in Greater China
• Table 6: Technologies and Manufacturing Services Offered by CMOs in Korea
• Table 7: Technologies and Manufacturing Services Offered by CMOs in Japan
• Table 8: GMP Certifications by CMOs in Greater China
• Table 9: GMP Certifications by CMOs in Korea
• Table 10: GMP Certifications by CMOs in Japan
• Table 11: Facility Size, Design and Capacity Planning by CMOs in Greater China
• Table 12: Facility Size, Design and Capacity Planning by CMOs in Korea
• Table 13: Facility Size, Design and Capacity Planning by CMOs in Japan

REGIONS COVERED IN ASIA

• Figure 1: Top 50 CMOs from all the Asian Regions

CHINA

• Figure 2: Manufacturing Projects Completed in the region
• Figure 3: Pricing Competitiveness in the region
• Figure 4: Company Based Services Analysis in the region
• Figure 5: Number of Services per company Analysis in the region
• Figure 6: Products Based Analysis in the region
• Figure 7: Manufacturing vs. Non-Manufacturing Employees in the region

TAIWAN

• Figure 8: Manufacturing Projects Completed in the region
• Figure 9: Pricing Competitiveness in the region
• Figure 10: Company Based Services Analysis in the region
• Figure 11: Number of Services per company Analysis in the region
• Figure 12: Products Based Analysis in the region
• Figure 13: Manufacturing vs. Non-Manufacturing Employees in the region

KOREA & JAPAN

• Figure 14: Manufacturing Projects Completed in the region
• Figure 15: Pricing Competitiveness in the region
• Figure 16: Company Based Services Analysis in the region
• Figure 17: Number of Services per company Analysis in the region
• Figure 18: Products Based Analysis in the region
• Figure 19: Manufacturing vs. Non-Manufacturing Employees in the region

JAPAN

• Figure 20: Manufacturing Projects Completed in the region
• Figure 21: Pricing Competitiveness in the region
• Figure 22: Company Based Services Analysis in the region
• Figure 23: Number of Services per company Analysis in the region
• Figure 24: Products Based Analysis in the region
• Figure 25: Manufacturing vs. Non-Manufacturing Employees in the region

INDIA

• Figure 26: Manufacturing Projects Completed in the region
• Figure 27: Pricing Competitiveness in the region
• Figure 28: Company Based Services Analysis in the region
• Figure 29: Number of Services per company Analysis in the region
• Figure 30: Products Based Analysis in the region
• Figure 31: Manufacturing vs. Non-Manufacturing Employees in the region

Market Analysis and Growth from 2010-2030

• Figure 32: Market Analysis and Growth from 2010-2030 for different Biologics
• Figure 31: Manufacturing vs. Non-Manufacturing Employees in the region

Ten years ago, it was hard for Chinese biopharmaceutical service companies to meet the requirements of a Western client. Today, there is a proliferation of companies such as WuXi Biologics, MabPlex, JHL Biotech and more.

Furthermore, recently in Asia:

• Eirgenix received approval from Japan's PMDA, opportuning it to sell to the Japanese market.

• Korea's Celltrion has budgeted $514 million over five years to build China's biggest biologics facility at a capacity of 120,000 litres, manufacturing Celltrion's own biologics and performing contract work for Chinese biotechs.

• New mammalian production lines established by AGC biologics to produce monoclonal antibodies (MAbs) and fusion proteins

Contract biomanufacturing in Asia is poised for growth. If you're keen on understanding the Asian CMO landscape, check out IMAPAC's latest release - a 300 page directory, Asia-Pacific Biologic CMO Directory, gives you a comprehensive analysis of the CMOs in Asia. The report provides detailed research and analysis of the Manufacturing Capacity, Facility Design, Product Lines, Regulatory Certifications, Team-Distribution, Financial Performance, Technologies Housed, and Facility Expansion Plans of 50+ CMOs in the Asian region from countries such as China, Taiwan, Korea, Japan, India, Singapore and more.

TABLE OF CONTENTS

SECTION 1

• PREFACE
• REPORT SCOPE & DATA COVERAGE
• IMAPAC'S RESEARCH METHODOLOGY

SECTION 2

• COMPANY-WISE DATA & ANALYSIS
  • COMPANY OVERVIEW
  • MANUFACTURING SITES
  • FACILITY DESIGN
  • PLANT CAPACITY
  • BATCH SIZE
  • GMP CERTIFICATION
  • PRODUCTS MANUFACTURED
  • MANUFACTURING SERVICES
  • PROJECTS
  • PARTNERSHIPS AND
  • COLLABORATIONS
  • CAPACITY PLANNING & FUTURE
  • EXPANSION
  • INTERVIEW
  • INDUSTRY NEWS & UPDATES
  • SWOT ANALYSIS
  • REFERENCES

• Greater China
  • 1. AMARAN BIOTECHNOLOGY
  • 2. BOEHRINGER INGELHEIM
  • 3. CMAB BIOPHARMA
  • 4. CELLULAR BIOMEDICINE GROUP
  • 5. CHIME BIOLOGICS
  • 6. CP GOUJIAN PHARMA
  • 7. EIRGENIX
  • 8. INNOVENT BIOLOGICS
  • 9. LONZA CHINA
  • 10. MABPLEX
  • 11. MYCENAX BIOTECH
  • 12. OBIO TECHNOLOGY
  • 13. ORIENT PHARMA
  • 14. SINOBIOWAY
  • 15. TARON SOLUTIONS
  • 16. UNICOCELL
  • 17. UNITED BIOPHARMA
  • 18. WUXI APPTEC
  • 19. 3S BIO

• Korea
  • 20. ANTEROGEN
  • 21. BINEX
  • 22. EUBIOLOGICS
  • 23. HANMI PHARMA
  • 24. KOLON LIFE SCIENCES
  • 25. MASTHERCELL
  • 26. SAMSUNG BIOLOGICS

• Japan
  • 27. AGC BIOLOGICS
  • 28. AJINOMOTO BIO- PHARMA
  • 29. BUSHU PHARMACEUTICALS
  • 30. HITACHI CHEMICAL
  • 31. ID PHARMA
  • 32. MEDINET
  • 33. PHARMABIO
  • 34. TAKARA BIO
  • 35. TOYOBO

• India
  • 36. CLONZ BIOTECH
  • 37. INTAS PHARMACEUTICALS
  • 38. KEMWELL BIOPHARMA
  • 39. STELIS BIOSOURCE
  • 40. SYNGENE
  • 41. ENZENE BIOLOGICS

• Australia
  • 42. CELL THERAPIES
  • 43. PFIZER CENTREONE
  • 44. LUINA BIO SEA
  • 45. BIOCON
  • 46. ESCO ASTER
  • 47. INNO BIOLOGICS
  • 48. LONZA AG SINGAPORE
  • 49. PT. KALBIO GLOBAL MEDIKA(KGM)
  • 50. TCELS

SECTION 3: REGION-WISE DATA & ANALYSIS OF CMO'S {REGIONS COVERED: CHINA, TAIWAN, JAPAN& KOREA, INDIA, AUSTRALIA & SEA}

• PRODUCTS MANUFACTURED: VACCINES - CELL THERAPY - RECOMBINANT PROTEINS & MABS - OTHERS

• TECHNOLOGIES HOUSED & MANUFACTURING SERVICES

• PRODUCTION LINES

• GMP CERTIFICATION

• FACILITY SIZE, DESIGN AND CAPACITY PLANNING

• TEAM SIZE & DISTRIBUTION

• PESTEL ANALYSIS

SECTION 4: OUR OTHER REPORTS

• BIBILIOGRAPHY
• DISCLAIMER
• ABOUT US
• OUR OTHER REPORTS